SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Storey Robert F.)) srt2:(2015-2019) srt2:(2017)
 

Search: (WFRF:(Storey Robert F.)) srt2:(2015-2019) srt2:(2017) > Comparison of Plate...

  • Gaglia, Michael A., Jr.Medstar Heart & Vasc Inst, Div Cardiol, Washington, DC 20007 USA. (author)

Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC,2017
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-322180
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-322180URI
  • https://doi.org/10.1016/j.amjcard.2017.01.002DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Ticagrelor, a potent platelet inhibitor, has primarily been studied in white patients. Platelet reactivity among black patients with acute coronary syndrome (ACS) on ticagrelor, however, is unknown. Our objective was to compare platelet reactivity in black versus white patients with ACS treated with ticagrelor. We conducted a prospective, pharmacodynamic study of 29 black patients with ACS treated with ticagrelor. Platelet reactivity was assessed at 1, 4, and 8 hours after a loading dose of ticagrelor 180 mg and at 30 days on a maintenance dose of ticagrelor 90 mg twice daily. Assays included light transmission aggregometry, VerifyNow P2Y12, and vasodilator-stimulated phosphoprotein. We provided comparison with a historical white cohort. Platelet reactivity among blacks with ACS on ticagrelor was similar to that in whites, except that blacks had lower values at 4 hours, 8 hours, and on maintenance therapy for light transmission aggregometry with 20 mu mol/L adenosine diphosphate. Among blacks, high-on-treatment platelet reactivity for all 3 assays was uncommon at 1 hour and nonexistent at 4 hours, 8 hours, and while on maintenance therapy. Blacks preloaded with clopidogrel (n = 17) had significantly lower results of VerifyNow (64 +/- 65 vs 198 +/- 86, p<0.001) and vasodilator-stimulated phosphoprotein (12.8 +/- 21.6 vs 58.9 +/- 19.9, p<0.001) at 1 hour compared with those with no clopidogrel prelOad. In conclusion, among patients with ACS receiving ticagrelor, levels of platelet reactivity in blacks are similar to that in whites. This suggests that the cardiovascular benefits of ticagrelor observed in the platelet inhibition and patient outcomes (PLATO) trial are likely to be observed in blacks and whites.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Lipinski, Michael J.Medstar Heart & Vasc Inst, Div Cardiol, Washington, DC 20007 USA. (author)
  • Lhermusier, ThibaultCtr Hosp Univ Toulouse, Div Cardiol, Toulouse, France. (author)
  • Steinvil, ArieMedstar Heart & Vasc Inst, Div Cardiol, Washington, DC 20007 USA. (author)
  • Kiramijyan, SarkisMedstar Heart & Vasc Inst, Div Cardiol, Washington, DC 20007 USA. (author)
  • Pokharel, ShreejanaMedstar Heart & Vasc Inst, Div Cardiol, Washington, DC 20007 USA. (author)
  • Torguson, RebeccaMedstar Heart & Vasc Inst, Div Cardiol, Washington, DC 20007 USA. (author)
  • Angiolillo, Dominick J.Univ Florida, Coll Med Jacksonville, Div Cardiol, Jacksonville, FL USA. (author)
  • Wallentin, Lars,1943-Uppsala universitet,Kardiologi(Swepub:uu)larswall (author)
  • Storey, Robert F.Univ Sheffield, Div Cardiol, Sheffield, S Yorkshire, England. (author)
  • Waksman, RonMedstar Heart & Vasc Inst, Div Cardiol, Washington, DC 20007 USA. (author)
  • Medstar Heart & Vasc Inst, Div Cardiol, Washington, DC 20007 USA.Ctr Hosp Univ Toulouse, Div Cardiol, Toulouse, France. (creator_code:org_t)

Related titles

  • In:American Journal of Cardiology: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC119:8, s. 1135-11400002-91491879-1913

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view